alt

7th International AIDS Society Conference on HIV Pathogenesis, Treatment & Prevention (IAS 2013)

June 30-July 3, 2013, Kuala Lumpur

IAS 2013: Management of Age-Related Conditions Is the Future of HIV Care

Other diseases are becoming far more important than AIDS for people with HIV who have consistent access and good response to antiretroviral treatment, and management of age-related comorbidities will become an increasingly important aspect of HIV medicine worldwide in the coming years, Steven Deeks argued in his keynote address yesterday at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013).alt

 

Read more:

IAS 2013: WHO Issues New HIV Recommendations Calling For Earlier Antiretroviral Initiation

New HIV treatment guidelines by the World Health Organization (WHO) launched today at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur recommend offering antiretroviral therapy to all HIV positive people at CD4 T-cell counts below 500 cells/mm3.

alt

Read more:

HIV i-Base and TAG Release 2013 Pipeline Report on HIV, Hepatitis C, and TB Therapies

HIV i-Base and the Treatment Action Group (TAG) released their 2013 Pipeline Report this week in conjunction with the International AIDS Society conference (IAS 2013) in Kuala Lumpur. The guide provides the latest status of drugs, diagnostics, and candidate vaccines for HIV, hepatitis C, and tuberculosis.

alt

 

Read more:

IAS 2013: Cure Research Is New Phase of HIV Therapy, Says U.S. AIDS Chief

"We are at the earliest dawn of a new stage of HIV therapy," said Carl Dieffenbach, director of the Division of AIDS at the U.Ss National Institute of Allergy and Infectious Disease (NIAID), speaking at the Towards an HIV Cure workshop on the opening day of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

alt

Read more:

IAS 2013: HIV as a Chronic Disease [VIDEO]

HIV has become a chronic disease for people who have access and respond to antiretroviral therapy, but it leads to persistent immune activation and inflammation that could cause problems as people with HIV reach their 60s, 70s, and 80s, Steven Deeks from the University of California at San Francisco explained at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.

alt

Read more: